When comparing the tumor molecular profile of one of the non-responding ES patients to another patient treated previously in their clinic that did respond to pazopanib, they found that FGFR3, FGFR4 and FLT4 (VEGFR3) genes were amplified only in the responder (30). This evidence concerns the gene FLT4 and Ewing sarcoma.